BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 10554037)

  • 21. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.
    Ferretti G; Curigliano G; Pastorino U; Cittadini A; Flamini G; Calabrò MG; De Pas T; Orlando L; Mandalà M; Colleoni M; Spaggiari L; Granone PL; Pagliari G; de Braud F; Fazio N; Goldhirsch A
    Clin Cancer Res; 2000 Jun; 6(6):2393-400. PubMed ID: 10873091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
    Casey G; Lopez ME; Ramos JC; Plummer SJ; Arboleda MJ; Shaughnessy M; Karlan B; Slamon DJ
    Oncogene; 1996 Nov; 13(9):1971-81. PubMed ID: 8934544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma.
    Koga T; Hashimoto S; Sugio K; Yoshino I; Mojtahedzadeh S; Matsuo Y; Yonemitsu Y; Sugimachi K; Sueishi K
    Clin Cancer Res; 2001 Jun; 7(6):1730-8. PubMed ID: 11410513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
    Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
    Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations.
    Boldrini L; Gisfredi S; Ursino S; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
    Lung Cancer; 2005 Dec; 50(3):309-17. PubMed ID: 16125276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
    Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS
    Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung.
    Kishimoto Y; Murakami Y; Shiraishi M; Hayashi K; Sekiya T
    Cancer Res; 1992 Sep; 52(17):4799-804. PubMed ID: 1324794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
    Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
    Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
    Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
    Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
    Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma.
    Kahlenberg MS; Stoler DL; Rodriguez-Bigas MA; Weber TK; Driscoll DL; Anderson GR; Petrelli NJ
    Cancer; 2000 Apr; 88(8):1814-9. PubMed ID: 10760757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
    Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
    Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China.
    Cao W; Chen X; Dai H; Wang H; Shen B; Chu D; McAfee T; Zhang ZF
    Cancer; 2004 Aug; 101(4):834-44. PubMed ID: 15305417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer.
    Horio Y; Takahashi T; Kuroishi T; Hibi K; Suyama M; Niimi T; Shimokata K; Yamakawa K; Nakamura Y; Ueda R
    Cancer Res; 1993 Jan; 53(1):1-4. PubMed ID: 8380124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx.
    Vielba R; Bilbao J; Ispizua A; Zabalza I; Alfaro J; Rezola R; Moreno E; Elorriaga J; Alonso I; Baroja A; de la Hoz C
    Laryngoscope; 2003 Jan; 113(1):167-72. PubMed ID: 12514403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
    Garinis GA; Gorgoulis VG; Mariatos G; Zacharatos P; Kotsinas A; Liloglou T; Foukas P; Kanavaros P; Kastrinakis NG; Vassilakopoulos T; Vogiatzi T; Field JK; Kittas C
    J Pathol; 2001 Jan; 193(1):55-65. PubMed ID: 11169516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas.
    Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E
    Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.